All News
Filter News
Found 806,157 articles
-
Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting
6/27/2020
Data Demonstrate In Vivo Adenine Base Editing Can Turn Off Either PCSK9 or ANGPTL3 in the Liver and Substantially Lower LDL Cholesterol or Triglyceride Levels
-
Statement from the Chief Public Health Officer of Canada on June 27, 2020
6/27/2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement
-
Domestic Violence Survivor Thrives After Assistance from Trauma Psychologist
6/27/2020
Post-traumatic stress disorder is a psychiatric disorder in which a person has difficulty recovering after experiencing a terrifying event.
-
Montreal Heart Institute announces COLCORONA trial in patients with COVID-19 passes futility test in interim analysisColchicine, a common drug to treat gout, is being evaluated as a potential treatment in the fight against coronavirus
6/27/2020
Montreal Heart Institute announced that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the independent data monitoring committee, following a futility analysis.
-
With Moderna on the precipice of launching its Phase III trial of 30,000 people for its COVID-19 vaccine, mRNA-1273, it is ramping up manufacturing capabilities.
-
One month after Vaxart announced the selection of its lead vaccine candidate for COVID-19, the Bay Area-based company said it has been selected to participate in the U.S. government’s Operation Warp Speed program.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
-
BioSpace Movers & Shakers, June 26
6/26/2020
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers. -
Despite the bleak challenges brought on by COVID-19, Bill Sibold, executive vice president of Sanofi Genzyme, is optimistic that some of the greatest discoveries in medicine and treating various diseases are within the grasp of the pharmaceutical industry.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
The lung model in Draper’s new organ-on-a-chip platform, PREDICT96, replicates the structure and function of human lung tissue from donors with multiple patient profiles on a 96-well plate, increasing assay throughput by 10-fold.
-
The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.
-
Shares of Zogenix were up more than 16% in premarket trading following the regulatory approval of the epilepsy drug Fintepla for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy, in patients ages two and above.
-
Resolutions of the Annual Shareholders' Meeting of Sartorius AG - June 26, 2020
6/26/2020
At virtual Annual General Shareholders' Meeting, shareholders granted discharge to the Executive Board and the Supervisory Board and approved the boards' proposals by a large majority.
-
CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes
6/26/2020
If granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease
-
FDA Approves New Therapy for Dravet Syndrome
6/26/2020
The U.S. Food and Drug Administration today approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. It is often characterized by severe and unrelenting
-
BetterLife Pharma Announces Consolidation of its Common Shares
6/26/2020
BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR) (OTCQB: BETRF) (FRA: NPAT) announces that it has consolidated its common shares on the basis of one new common share for ten old common shares (the "Consolidation"). As a result, the previously issued and outstanding 172,109,851 common
-
Virender Ahluwalia Joins Radiant Ventures, Inc. as Chief Financial Officer
6/26/2020
Radiant Ventures, Inc., a cannabis supply chain management company with manufacturing and distribution operations in California, today announced the hiring of Virender Ahluwalia as Chief Financial Officer
-
Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe
6/26/2020
WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective June 22nd, 2020, it has entered into a manufacturing, distribution and sales agreement with Cafféluxe for an initial two-year term.
-
Intact Vascular Announces Positive One-Year Data from TOBA II BTK Clinical Trial in VIVA Late-Breaking Session
6/26/2020
Durable Below-the-Knee Vascular Implant for Post-Angioplasty Dissection Repair Demonstrates Sustained Success Saving Limbs